In order to acquire a comprehensive view of the proteome in liver cancer cells after treatment with SOAT1-targeting compounds, we simultaneously assessed HepG2 cells treated with nevanimibe and nilotinib for 12 h to detect protein changes by liquid chromatography tandem mass spectrometry (LC–MS/MS), and 0.1% DMSO was used as a control (n = 3) (Figure S3a). The gene discussed is SOAT1; the disease is liver cancer.